Phase I/II Dose-Escalation Study of the Pan-Histone Deacetylase (HDAC) Inhibitor PCI-24781 in Lymphoma.
Phase of Trial: Phase I/II
Latest Information Update: 02 Nov 2016
At a glance
- Drugs Abexinostat (Primary)
- Indications Cutaneous T cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pharmacyclics
- 19 Oct 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 04 Apr 2014 Primary endpoint added as reported by ClinicalTrials.gov.
- 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.